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Abstract
Background & Aims
Focal nodular hyperplasias (FNHs) are benign liver lesions considered to be a hyperplastic response to increased blood flow in normal
liver. In contrast, FNH-like occur in cirrhotic liver but share similar histopathological features. To identify biological pathways
deregulated in FNH, we conducted a transcriptome analysis.
Methods
Gene expression profiles obtained in FNH and normal livers were compared. Differentially-expressed genes were validated using
quantitative-RT-PCR in 70 benign liver tumors including FNH-like lesions.
Results
Among the deregulated genes in FNHs, 19 displayed physiological restricted distribution in the normal liver. All six perivenous genes
were up-regulated in FNH, whereas 13 periportal genes were down-regulated. Almost all these genes are known to be regulated by β
-catenin. Glutamine synthetase was markedly overexpressed in anastomosed areas usually centered on visible veins. Moreover,
activated hypophosphorylated -catenin protein accumulated in FNH in the absence of activating mutations. These results suggest theβ
zonated activation of the -catenin pathway in FNH, whereas the other benign hepatocellular tumors, including FNH-like lesions,β
demonstrated an entirely different pattern of -catenin expression.β
Conclusions
In FNH, increased activation of the -catenin pathway was found restricted to enlarged perivenous areas. FNH-like nodules may haveβ
a different pathogenetic origin.
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Introduction
Focal nodular hyperplasia (FNH), first described by Edmondson ( ), is the second most common benign liver tumor, outnumbered1
only by hemangioma. FNH usually occurs in women 20 50 years old. A relation between FNH and oral contraceptive use has been–
reported but is disputed ( ). Classical FNH is characterized by a central stellate fibrous region containing malformed vascular structures (2 3
). The solitary central artery with high flow and the absent portal vein give the lesions a characteristic radiological appearance ( ) in more4
than 80  of FNH cases. However, some classical FNHs, mainly those smaller than 3 cm, have no central scar at pathological examination%
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( ). In all cases, the treatment of FNH is conservative because there is very low risk of complications such as bleeding, and malignant5
transformation has not yet been proven ( ).6
FNH typically occurs in normal or almost normal liver. The lesion is multinodular, composed of nearly normal hepatocytes arranged
in 1 2 cell-thick plates. Bile ductules are usually found at the interface between hepatocytes and fibrous regions ( , ). It is thought that– – 7 8
increased arterial flow hyperperfuses the local parenchyma, leading to secondary hepatocellular hyperplasia. FNH is therefore considered a
hyperplastic response to increased blood flow, rather than a neoplastic process ( , , ). Various vascular abnormalities such as3 9 10
telangiectases, hereditary hemorrhagic telangiectasia, arteriovenous malformation, and anomalous venous drainage may be present,
especially in patients with multiple FNHs.
Clonal analysis demonstrated the reactive polyclonal nature of liver cells in FNH in 60 100  of cases, depending on the series (– % 11–15
). Other studies analyzing chromosome gains and losses by comparative genomic hybridization, allelotyping, or karyotyping identified
chromosome alterations indicating a clonal origin of the FNH nodules in 14 50  of cases ( , , ). However, genetic analysis of FNH– % 2 15 16
did not demonstrate somatic gene mutations in , ,  or  ( , , ). Recently, it was shown that two angiopoietinCTNNB1 TP53 TCF1 APC 15 17 18
genes (  and ) involved in vessel maturation have altered mRNA expression levels, with a consistently increased ANGPT1 ANGPT2
/  ratio in FNH.( , )ANGPT1 ANGPT2 14 15
Focal nodular hyperplasia-like (FNH-like) nodules are lesions arising in cirrhotic liver that closely resemble FNH at both the
morphological and radiological levels ( , ). It has been hypothesized that FNH-like nodules arise as a local hyperplastic response to19 20
vascular alterations ( , ) known to occur in liver cirrhosis ( ). However, the exact pathogenesis of FNH-like nodules remains to be20 21 3
elucidated.
To better understand the pathophysiology of FNH, we searched for genes deregulated in FNH by conducting a combined cDNA and
oligonucleotide transcriptomic analysis exploring expression of more than 15,000 different genes. In this experiment, transcriptome
profiles of eight FNHs were compared to six non-tumor liver samples. After the analysis, selected genes belonging to the most strongly
activated or inactivated pathways were validated using quantitative RT-PCR in a larger series of 70 benign liver tumors including FNH,
hepatocellular adenomas (HCA), macroregenerative and dysplastic cirrhotic nodules, and FNH-like lesions.
Material and Methods
Patients and Samples
A series of 11 FNHs, 15 HCAs, 6 normal liver tissues including samples taken at a distance from HCAs ( ), FNHs ( ), and[ 3 1
hemangiomas ( ) , 8 cirrhotic nodules including 3 high-grade dysplastic nodules (HGDN), 1 low-grade dysplastic nodules (LGDN), and 42 ] [
macroregenerative nodules (MRN) , 11 FNH-like nodules, and 19 samples of random cirrhotic liver including samples taken at a distance] [
from hepatocellular carcinoma ( ), FNH-like nodules ( ), and dysplastic nodules ( )  were collected at the University Hospital of8 7 4 ]
Bordeaux and Leuven. HCAs were classified as described previously;( , ) five cases were HNF1 -inactivated, five were -catenin22 23 α β –
mutated, and the remaining five HCAs were non-mutated and inflammatory. For all cases included in this study, full clinical and
morphological data were available and are summarized in . Frozen tissue samples were available for all cases, and the prerequisiteTable 1
to include samples in the study was an adequate sampling of fresh and fixed liver tissue. This study was conducted with the authorization
of our local ethics committees (CCPPRB Paris Saint-Louis, France, and Committee from the University Hospitals, Leuven).
For each case, tissue from surgical samples including the nodules and corresponding non-tumor tissue was cut into thin slices. A
representative portion of the nodule, as well as of the non-tumor liver, was immediately frozen in liquid nitrogen and stored at 80 C until− °
used for molecular studies. Paraffin tissue sections were routinely stained with H&E and Masson s trichrome for diagnostic purposes.’
Pathological diagnosis of FNH and HCA was made on the basis of classical criteria ( , ).7 8
DNA and RNA were extracted as described previously.( ) DNA was quantified by fluorometry (Fluoroskan Thermo Labsystem,15
Cergy-Pontoise, France). The quality of DNA and RNA was assessed by gel electrophoresis followed by staining with ethidium bromide,
and degraded samples were excluded. RNA was accepted for quantitative RT-PCR if the 28S/18S ratio was greater than 1. For microarray
analysis, RNA was analyzed by Agilent Bioanalyzer profiling, and RNA was qualified if the 28S/18S ratio was greater than 1.5 and if the
RNA was not degraded.
Microarray Analysis
Transcriptional profiling of FNH lesions and non-tumor liver tissues was performed using two different microarray approaches
(Affymetrix oligonucleotide GeneChips U133 and a cDNA microarray). Minimum Information about a Microarray Experiment
(MIAME)-compliant data were deposited in Gene Expression Omnibus (GEO) at NCBI ( ) and arehttp://www.ncbi.nlm.nih.gov/geo/
accessible through GEO series accession number GSE9536. The characteristics of the in-house manufactured cDNA array are described in
Graudens et al. 2006 Additional data file 2 ( ). The detailed procedure for the gene array analysis is provided in the 24 supplementary
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. Gene ontology (GO) categories that were significantly over-represented in FNH were determined by thematerial and methods
hypergeometric test using the web-based tool GOTree Machine (GOTM) ( ). Distribution in GOhttp://bioinfo.vanderbilt.edu/gotm/
categories of genes significantly up-regulated and down-regulated in FNH were compared to the distribution of the overall genes included
in the HG-U133A Affymetrix array. GO categories were considered significantly enriched when the -value was less than 0.01.P
Quantitative RT-PCR
Quantitative RT-PCR was performed as described previously ( ) using pre-designed primers and probe sets from Applied Biosystems25
for the detection of , , , , , ,  ( ),  and . Ribosomal 18S RNA ( )R18S NTS HAL ANGPT1 ANGPT2 GLUL GPR49 LGR5 SDS CTNNB1 R18S
was used for the normalization of expression data. The relative amount of mRNA in samples was determined using the 2- CT method,ΔΔ
where CT  (CTtarget-CTR18S)sample  (CTtarget-CTR18S)calibrator. Final results were expressed as the -fold differences in targetΔΔ = − n
gene expression in tested samples compared with the mean expression value of non-tumor tissues.
Immunohistochemistry
Immunostaining was performed on 5- m sections of formalin-fixed, paraffin-embedded liver samples using a Dako autostainer. Aμ
monoclonal antibody against catenin (1:200, BD Biosciences 610153) and a biotinylated mouse antibody against glutamine synthetaseβ–
(1:400, BD Biosciences) were used for immunostaining. Prior to immunostaining, endogenous peroxidase was blocked, and antigen
retrieval was performed in a bain-marie with 0.001 M citrate buffer, pH 6, at 98 C. Detection was amplified by the Dako Envision system.°
Western Blotting
Total protein extracts were obtained after tissue homogenization in RIPA lysis buffer (Santa Cruz Biotechnology), and protein
concentration was determined using a Pierce BCA protein assay kit. A mouse monoclonal antibody specific for the dephosphorylated,
active form of -catenin (Upstate Biotechnology, 05-665) was used at a 1:500 dilution. Rabbit polyclonal antibodies were used at a 1:500β
dilution for the detection of GSK3  and phospho GSK3  ser9 (Cell Signalling). Ponceau Red staining was used to evaluate protein loadingβ β
and to normalize the signals. Detection was performed using the ECL SuperSignal West Pico Chemiluminescent Substrate (Pierce) and
horseradish peroxidase-conjugated anti-mouse IgG (1:4000, Amersham) as the secondary antibody.
Statistical Analysis
All reported values are mean  SD. Statistical analysis was performed using GraphPad Prism version 4 software, and significance was±
determined using the nonparametric Mann-Whitney test for unpaired data. A difference was considered significant at  < 0.05.P
Results
Identification of Overexpressed Genes Encoding Proteins of the Extracellular Matrix
Analysis of the Affymetrix and cDNA microarray results revealed 240 and 284 genes that were respectively significantly up- and
down-regulated in FNH compared to control non-tumor liver samples ( ). We analyzed these sets of genes toSupplementary Table 1
identify biological pathways that were specifically altered. Using a gene ontology-based analysis, we identified several GO categories that
were significantly over-represented in FNH ( ). Among the up-regulated genes in FNH, the extracellular matrix andSupplementary Table 2
cell adhesion terms achieved the highest degree of significance (   6.10  and   8.10  respectively) ( ). The overexpression ofP = 22− P = 12− Table 2
the genes encoding proteins of the extracellular matrix is consistent with the presence of fibrosis in most cases of typical FNH, particularly
in the fibrous scar area. In FNH, fibrosis appears as a blue area as revealed using trichrome staining ( ) or is alsoFig. 1A and B
immunostained using anti-collagen IV antibodies ( ). This profile of expression is characteristic of the TGF- -dependentFig. 1C E– β
pathways. Accordingly, we identified a two-fold overexpression of the TGF- 1 gene in FNH, as well as overexpression of other key genesβ
involved in fibrogenesis such as  and . A smooth muscle actin (SMA) staining was observed in myofibroblasts present atPDGFA PDGFRB
the periphery and within the fibrotic area ( ). These results are consequently consistent with an activation of the TGF  pathwayFig. 1G H– β
in cells located around the central fibrous scar.
Expression of Zonated Genes is altered in FNH
Nineteen regulated genes were identified whose expression is physiologically zonated in the hepatic lobule. In addition, the expression
of these genes is known or was previously suggested to be regulated by -catenin ( ) ( , ). Among these, the expression of 13β Table 3 26 27
genes physiologically expressed in the periportal area was down-regulated in FNH. Moreover, the expression of six genes normally
expressed in the perivenous area was up-regulated in FNH nodules, suggesting altered zonation in FNH. To further explore this
phenomenon, we analyzed the architectural distribution of glutamine synthetase (GS), a well characterized overexpressed protein in FNH
that is physiologically expressed in only one or two plates of hepatocytes immediately adjacent to the central veins in normal liver (Fig. 1I
). In FNH, we observed the overexpression of GS in hepatocytes that were heterogeneously distributed in the nodules. A systematic
analysis of the staining architecture showed a non-random distribution of the highly stained hepatocytes over relatively large areas, often
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anastomosed in map-like  patterns centered on central veins, whereas they remained at a distance from fibrous bands ( ).“ ” Fig. 1J and 1K
This zonal distribution pattern of GS expression in FNH strongly differs from the homogeneous staining usually observed in -cateninβ –
mutated adenomas ( ).22
The expression of , the gene encoding GS, is known to be up-regulated by -catenin ( ). Accordingly, we found that GLUL β 28 GLUL
mRNA overexpression significantly correlated with a slight but significant  (the gene encoding -catenin) mRNA overexpressionCTNNB1 β
in FNH compared with normal liver tissues (    0.33,   0.016, ). However, immunohistochemical analysis of FNH nodulesr 2 = P = Fig. 1L
using a -catenin antibody did not show any abnormal -catenin localization. -catenin was membranous in all hepatocytes, withoutβ β β
significant cytoplasmic or nuclear accumulation, even in hepatocytes that overexpressed GS ( ). Despite no detectable variationFig. 1M O–
of the total -catenin expression in hepatocytes of FNH, we observed the overexpression of the active, unphosphorylated -catenin proteinβ β
in FNH compared to normal liver samples ( ). Consistent with -catenin activation in FNH, our transcriptomic analysis revealed atFig. 1P β
least seven additional genes known to be regulated by the -catenin pathway but whose physiological localization in the lobule wasβ
unknown ( ). Taken together, these results suggest the up-regulation of the -catenin signaling pathway in areas surrounding theTable 3 β
veins of FNH nodules. This up-regulation is related to overexpression of the active form of -catenin in the absence of β CTNNB1
-activating mutations, as evidenced in 11 screened FNH samples. As activated -catenin signaling is a known readout of Wnt signaling, weβ
compared the expression levels of Wnt regulators in FNH and normal liver tissues. We did not find any significant differences in GSK3β
and phospho-GSK3  ser9 expression using western blotting ( ). Similarly, no significant difference was observedβ Supplementary Fig. 1
regarding the expression levels of ,  (14 genes analyzed),  (Frizzled receptors) (9 genes analyzed),  (3 genesAXIN1 WNT FZD DVL
analyzed),  and  mRNA ( ). Surprisingly, against the hypothesis of a -catenin activation through APCLRP5 LRP6 Supplementary Fig. 2 β
silencing, we found a mild but significant overexpression of the  transcript in FNH (2-fold) when compared to non-tumor livers (APC
).Supplementary Fig. 2
Expression of the FNH-deregulated Genes in Other Types of Benign Hepatocellular Tumors
In a series of 70 liver samples including cirrhotic and normal tissues, different subtypes of adenomas, typical FNH nodules, and
FNH-like, dysplastic, and macroregenerative nodules developed in cirrhosis, we examined the specificity of FNH-deregulated genes as
identified in our microarray analysis or as described previously in the literature (all the data are provided in the ).supplementary Table 3
The ratio of expression of two angiopoietin genes, , which was previously shown to be increased in FNH, ( )ANGPT1/ANGPT2 29
demonstrated a significantly increased mean -fold change of expression (9.5  6.5) in FNH compared with non-tumor liver tissues.±
However, in our series, the  ratio also increased significantly, although at a lower level, in cirrhosis-related samplesANGPT1/ANGPT2
including random cirrhosis (3.9  0.4), regenerative and dysplastic nodules (7.5  0.9), and FNH-like nodules (4  0.6) ( ). In contrast,± ± ± Fig. 2
the overexpression of the  transcript, which encodes neurotensin, was observed specifically in FNH ( ). The ratio of expression ofNTS Fig. 2
 was fully specific and sensitive to discriminate FNH from the other benign tumors ( ).NTS/HAL Fig. 2
The microarray results indicating significant overexpression in FNH of the -catenin target genes , , and  wereβ GLUL GPR49 TBX3
confirmed using quantitative RT-PCR (  and data not shown). Interestingly, overexpression was lower than that observed in -cateninFig. 2 β
mutated adenomas. The other subtypes of lesions demonstrated normal or significantly decreased expression levels of the -catenin target– β
genes compared to FNH ( ). Similarly, two periportal genes,  and , which encode the serine dehydratase and histidineFig. 2 SDS HAL
amomnia lyase, respectively, were down-regulated specifically in FNH and -catenin mutated adenomas ( ).β – Fig. 2
Interestingly, FNH-like nodules demonstrated an expression profile similar to those of other cirrhotic samples but different from the
profile observed in typical FNH. In particular, in FNH-like nodules, the -catenin induced perivenous genes encoding GS and GPR49β –
were significantly down-regulated compared with non-tumor liver and FNH nodules ( ). Consistent with this result, very littleFig. 2
parenchymal GS staining was observed in FNH-like nodules ( ). Some parenchymal staining was observed around venous structures,Fig. 3
in addition to the ductular reaction, of FNH-like nodules. Because ductules occupy only a small area of FNH-like nodules and no
parenchymal GS staining was detectable, no GS over-expression was observed at the RT-PCR level. However, the immunohistochemical
pattern of GS expression was distinct from that of FNH, thus confirming that FNH-like nodules represent a separate entity. Moreover, in
FNH-like nodules, neurotensin and the selected genes displaying periportal localization were not found differentially expressed when
compared to non-tumor liver tissues by quantitative RT-PCR ( ). In fact, FNH-like nodules showed similar expression patterns asFig. 2
other cirrhotic lesions. Consequently, our results support the idea that FNH-like nodules have a pathophysiological origin different from
that of typical FNH.
Discussion
In the present work, we carried out a transcriptomic analysis which revealed the molecular pathways altered in FNH. For the first time,
activation of the -catenin pathway was demonstrated in these tumors. Recently, -catenin was identified as a master actor of hepatocyteβ β
proliferation, liver regeneration, hepatocyte metabolism, and liver development and as a master regulator of liver zonation ( , ). In26 30–34
normal hepatocytes, -catenin and its known target genes, such as GS, are expressed exclusively in the immediate perivenous areas ( , β 28 35
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). This zonated defined pattern of expression differs from that observed in -catenin activated HCA or carcinoma, which usually showsβ –
more diffuse cytoplasmic GS staining and nuclear -catenin staining, in accordance with the monoclonal origin of the -catenin activatingβ β –
mutations in these tumors ( , ).8 30
In FNH, -catenin activation showed a heterogeneous distribution along the hepatocellular nodules, with a characteristic architecturalβ
distribution over relatively large areas, sometimes centered on visible veins and usually remaining at a distance from fibrous bands. This
specific -catenin expression pattern may be interpreted as the result of an altered hepatocyte zonation in FNH leading to increased β β
-catenin gradient starting from the veins. Because FNHs are most frequently polyclonal tumors, it is not surprising to find a heterogeneous
distribution of -catenin pathway activation in the absence of gene mutation ( , ).β 11 13–16
In FNH, sinusoidal blood flow is modified by arteriohepatic hyperperfusion, and sinusoids are directly irrigated by inlet arterioles
coming from fibrous septa ( , ). The abnormal arteries drain indirectly into sinusoids via capillaries in the fibrous septa, leading to a3 10
modified sinusoidal endothelial cell phenotype ( , ). This situation is entirely different from the normal lobulation of the liver (9 36–38 Fig. 4
). Because the fibrous septa with arteries are the location of blood inflow, they can be considered portal tract equivalents,  i.e., they have“ ”
the artery and the ductular reaction but not that of the bile duct and vein ( ). In FNH, we observed an extension from the centrolobular39
equivalent area toward the portal tract equivalent. The blood composition may likely participate in zonal/restricted -catenin activation.β
One could therefore hypothesize that the almost completely arterial inflow in FNH, without portal venous blood inflow, may cause β
-catenin activation to extend much farther toward the inflow area than in normal liver or in cirrhotic liver, where there is still some portal
venous inflow. The mechanism of -catenin activation in FNH remains to be elucidated since we did not identify any alteration of the mainβ
known regulators of the Wnt pathway. As such, we did not observe any variations in the expression level of negative regulators such as
GSK3 ,  and  and positive regulators such as ,  (Frizzled),  and  (  and ). Moreover,β AXIN1 APC WNT FZD DVL LRP Supplementary Fig. 1 2
in FNH we did not identify any activating mutations of -catenin. Furthermore a previous work showed the lack of  and β AXIN1 APC
inactivating mutations in those tumors ( ).17
Activation of the -catenin pathway in FNH could consequently contribute to tumor formation as -catenin may promote hepatocyteβ β
proliferation and regeneration. However, in contrast to an activating mutation, hepatocytes in FNH remain sensitive to repression of the β
-catenin pathway in regions surrounding fibrosis. The present study also shows that fibrosis in FNH is related to the overexpression of
several genes encoding extracellular matrix proteins, in addition to increased TGF-  expression. This result is in agreement with β in situ
hybridization experiments in which a high expression level of TGB- 1 was detected in mesenchymal cells in FNHs ( ). TGF- 1 is aβ 40 β
multifunctional cytokine that is involved in development and tissue differentiation through its effects on cell proliferation, migration,
differentiation, and apoptosis. TGF -1 is also important in the pathological process of fibrosis. Interestingly, TGF-  and Wnt/ -cateninβ β β
pathways regulate a number of common processes during embryonic development, such as the patterning of imaginal discs in Drosophila
and tissue specification and organogenesis in vertebrate embryos ( ). Several recent reports have highlighted the complex, intertwined41
nature of the two signaling pathways ( ). Zhang and collaborators supported the hypothesis that -catenin in renal epithelial cells, rather42 β
than in mesenchymal cells, may suppress TGF- 1 dependent signaling ( ). Furthermore, analysis of TGF- 1 transgenic mice showedβ – 43 β
reduced GS expression resulting from apoptosis of GS-positive hepatocytes ( ). However, Lotz and collaborators showed that in FNH,44
TGF-  activation was not related to increased hepatocyte apoptosis ( ). Consequently, additional functional analyses of the interplayβ 40
between TGF-  and -catenin pathways in hepatocytes are required to better understand the pathogenesis of FNH. One hypothesis couldβ β
be proposed in which TGF  overexpression in FNH may occur to counteract the proliferative effect of -catenin activation. In anotherβ β
hypothesis, -catenin activation could represent a response to an abnormal TGF -activation in FNH. Considering that most frequent FNHβ β
remain stable, activation of these pathways is probably tightly controlled to balance cell proliferation rate.
Another important finding of our study was that FNH-like nodules gene expression profile significantly differs from that of typical
FNH nodules. In particular, FNH-like nodules did not show -catenin activation. Moreover, they did not exhibit increased β NTS/HAL
expression ratio as did typical FNH. None of the genes tested in FNH-like nodules demonstrated a significantly different level of
expression from that of random cirrhotic samples or cirrhotic dysplastic nodules. Our results demonstrate that, despite an enhancement of
the signal during the arterial phase in MR/CT imaging of both types of nodules, typical FNH and FNH-like nodules derive from different
pathophysiological processes. The specific markers identified in the present study will be useful tools to correctly diagnose and classify
benign lesions of the liver, including the different molecular subtypes of HCA ( ).22
In conclusion, abnormally zonated -catenin activation is a particular feature of typical FNH that may explain the slight polyclonalβ
over-proliferation of hepatocytes at the origins of the lesions. In contrast, FNH-like nodules, as random cirrhosis, do not share the same
molecular defect, indicating a different pathogenesis. Finally, molecular and immunohistochemical markers will be useful tools in clinical
practice to diagnose and classify benign hepatocellular tumors.
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Abbreviations
 FNH: Focal Nodular Hyperplasia
 HCA: hepatocellular adenoma
 RT-PCR: Reverse Transcriptase Polymerase Chain Reaction
 GLUL: gene coding for glutamine synthetase
 GS: Glutamine Synthetase
 AAT1: alpha-1 antitrypsin deficiency
 APC: adenomatosis polyposis coli
 CTNNB1: gene coding for beta-catenin
 ANGPT1 and ANGPT2: genes coding for angiopoietin 1 and 2, respectively
 HNF1α: hepatocyte nuclear factor 1 alpha
 TCF1: transcription factor 1 (gene coding for HNF1alpha)
 HGDN: high-grade dysplastic nodules
 LGDN: low-grade dysplastic nodules
 MRN: macroregenerative nodules
 GSK3beta: glycogen synthase kinase 3 beta
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Figure 1
Expression of the TGF  and -catenin pathways in FNHβ β
(A, B) Two serial sections of FNH stained with Masson s trichrome (TC) showing fibrous bands stained in blue. (C, D, E) Immunostaining of’
collagen IV (Col IV) in NTL (C) and FNH (D, E). In NTL, some Co IV fibrils are found around vessels and biliary channels in portal tract; in
FNH, immunostaining showed a diffuse pattern with more intense expression in and around fibrous bands (black arrows), also found along
sinusoids. (F, G, H) Immunostaining of smooth muscle actin (SMA) in NTL (F) and FNH (G, H). In NTL, SMA is expressed only by
myofibroblasts of vascular walls (black arrow): artery (right), central vein (left); in lobules, only a few hepatic stellate cells (HSC) express
faintly SMA (red arrow); in FNH, SMA is overexpressed by myofibroblasts in and around fibrous bands (black arrow) and veins (red arrow).
(I, J, K) Immunohistochemistry using GS antibody in non-tumor liver (NTL) (I) and FNH (J, K). In NTL, GS is expressed only by
hepatocytes of 1 or 2 centrolobular plates (arrow); in FNH, typical aspect of GS staining in a map-like  pattern (J); this large GS  area is“ ” +
centered on a central vein and remains at a distance from the fibrous band (K). (L) Correlation between  and  mRNAGLUL CTNNB1
overexpression in FNH and in NTL. Expression of  (encoding GS) and  (encoding -catenin) was measured in FNH (n  11)GLUL CTNNB1 β =
and in NTL (n  6) with quantitative RT-PCR. (M, N, O) Immunohistochemistry using a total -catenin antibody in NTL (M) and FNH (N,= β
O). In NTL, -catenin immunostaining showed a normal membranous staining in hepatocytes and an obvious cytoplasmic staining in biliaryβ
cells (arrows); in FNH, no cytoplasmic nor nuclear -catenin staining was observed in hepatocytes that overexpressed GS, but there wasβ
normal membranous expression. In fibrotic areas, biliary cells of the ductular reaction showed normal strong cytoplasmic expression of β
-catenin (arrows). (P) Overexpression of active, unphosphorylated -catenin in FNH (n  4) compared with NTL tissues (n  4).β = =
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Figure 2
Validation of deregulated genes in well-defined subtypes of benign liver tumors
Gene expression was examined by quantitative RT-PCR in different subgroups of samples: N, normal liver samples (   6); FNH-like nodulesn =
(   11); Cirr N, dysplastic or macroregenerative nodules in cirrhosis (   8); Cirr, cirrhotic nodules (   19); FNH (   11); Inflam. Ad,n = n = n = n =
inflammatory adenomas (   5); HNF1 Ad, HNF1 -mutated adenomas (   5); -cat. Ad, -catenin mutated adenomas (   5). All resultsn = α n = β β – n =
were normalized to the mean expression level of normal liver samples. When box-and-whiskers graphs are used, the line in the middle is the
median, the box extends from the 25  to 75  percentile, and the whiskers extend to the lowest and highest values. Significant results of theth th
Mann-Whitney test comparing expression of each subgroup of tumors with normal liver samples are indicated as follows:  < 0.01,  <**P *P
0.05.
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Figure 3
Expression of glutamine synthetase (GS) in FNH-like nodule and cirrhosis. (A) FNH-like nodule with a diameter of 9 mm (left side) and some
surrounding regenerative cirrhotic nodules (S). The FNH-like nodule contains several septa that are surrounded by reactive ductules (arrows).
(B) GS-staining of the FNH-like nodule and surrounding regenerative cirrhotic nodules. In the FNH-like nodules, there is staining of the
reactive ductules (arrows), but parenchymal staining is very limited, in contrast to focal nodular hyperplasia. In the surrounding cirrhotic
nodules, there is some patchy parenchymal staining, mostly related to venous structures (arrowheads).
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Figure 4
Schematization of glutamine synthetase staining in normal liver ( ) and in FNH ( ). GS staining is indicated in brown. CV, central vein; PT,A B
portal tract; V, vein; DV, dystrophic vessels; fib, fibrosis (in grey); DR, ductular reaction; hep GS , glutamine synthetase-positive+
hepatocytes; hep GS , glutamine synthetase-negative hepatocytes.−
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Table 1















Normal liver 6 6 48 14± 6/0 -
FNH 11 8 41  7± 8/0 5.1  1.8± 2 -
FNH-like 11 6 62  7± 2/4 1.2  0.5± 2 HCV  3=
Alcohol  2=
AAT1  1=
Dysplastic and macroregenerative cirrhotic
nodules
8 6 55  4± 3/3 1.1  0.5± 4 HCV  3=
Alcohol  3=
Cirrhosis 19 16 60  7± 2/14 HCV  9=
HBV  3=
Alcohol  5= *
AAT1  1=
Inflammatory HCA 5 5 39  7± 5/0 5  3± 3 -
HNF1 -mutated HCAα 5 5 36  12± 4/1 2.8  2.9± 3 -
-cateninβ –mutated HCA 5 5 47  14± 4/1 3.3  2.2± 2 -
 
* Two patients presented simultaneously with alcohol intake and hepatitis B viral (HBV) or hepatitis C viral (HCV) infection. AAT1: alpha-1 antitrypsin deficiency.
Table 2
Genes Encoding Extracellular Matrix Proteins Up-regulated in FNH
Gene Symbol Gene Name Affymetrix Ratio 4FNH/4NTL cDNA array Ratio 7FNH/8NTL
Extracellular matrix
COL1A1 Collagen. type I. alpha 1 19.8 nd
COL1A2 Collagen. type I. alpha 2 9.3 nd
COL3A1 Collagen. type III. alpha 1 9.8 nd
COL4A1 Collagen. type IV. alpha 1 3.3 nd
COL4A2 Collagen. type IV. alpha 2 5 nd
COL5A1 Collagen. type V. alpha 1 4.3 2.4
COL5A2 Collagen. type V. alpha 2 3.8 nd
COL6A1 Collagen. type VI. alpha 1 2.5 nd
COL6A2 Collagen. type VI. alpha 2 2 1.4
COL15A1 Collagen. type XV. alpha 1 3.1 1.7
CSPG2 Chondroitin sulfate proteoglycan 2 (versican) 5.8 1.7
DCN Decorin 1.9 na
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 9.5 nd
FBLN2 Fibulin 2 2.6 nd
FBLN5 Fibulin 5 4 nd
FBN1 Fibrillin 1 (Marfan syndrome) 3.2 nd
FLRT2 Fibronectin leucine-rich transmembrane protein 2 2.1 nd
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HSPG2 Heparan sulfate proteoglycan 2 (perlecan) 2.9 ns
IBSP Integrin-binding sialoprotein (bone sialoprotein II) 2.4 nd
LAMA2 Laminin. alpha 2 (merosin) 2.2 2.5
LAMB2 Laminin. beta 2 (laminin S) 1.8 nd
LOXL4 Lysyl oxidase-like 4 nd 2.9
LUM Lumican 5.7 1.8
MGP Matrix Gla protein 3.4 1.5
MMP11 Matrix metalloproteinase 11 (stromelysin 3) 3.1 2.5
MMP2 Matrix metalloproteinase 2 2.1 ns
PRG4 Proteoglycan 4 −2.2 nd
SPARC Secreted protein. acidic. cysteine-rich (osteonectin) 1.9 1.4
SPON2 Spondin 2 2.8 ns
TFPI2 Tissue factor pathway inhibitor 2 6.1 na
TGFBI Transforming growth factor, beta-induced, 68 kDa 2.3 1.5
THBS2 Thrombospondin 2 5.3 nd
TIMP1 Tissue inhibitor of metalloproteinase 1 3.4 ns
TNC Tenascin C (hexabrachion) 11.2 ns
TNXB Tenascin XB 2.1 nd
VWF Von Willebrand factor 23.2 nd
Cell matrix adhesion
ADAM15 A disintegrin and metalloproteinase domain 15 (metargidin) ns 2.3
EMCN Endomucin 7.3 nd
GPLD1 Glycosylphosphatidylinositol specific phospholipase D1 −2.4 −1.8
ITGA6 Integrin, alpha 6 2.1 1.5
ITGAV Integrin, alpha V (vitronectin receptor, antigen CD51) 2 ns
ITGBL1 Integrin, beta-like 1 (with EGF-like repeat domains) 18.8 nd
SGCE Sarcoglycan, epsilon −2 nd
XLKD1 Extracellular link domain containing 1 −6.6 nd
Fibrogenesis pathway
TGFB1 Transforming growth factor. beta 1 2.2 −1.2
ENG Endoglin (Osler-Rendu-Weber syndrome 1) 2.7 1.4
TGIF2 TGFB-induced factor 2 (TALE family homeobox) ns −2.2
PDGFA Platelet-derived growth factor alpha polypeptide 2.3 nd
PDGFRB Platelet-derived growth factor receptor, beta polypeptide 2.2 1.9
TGFB1I1 Transforming growth factor beta 1 induced transcript 1 ns 1.9
ns: not significant; na: not analyzed; nd: not done; NTL: non tumor-livers
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Table 3
Known Zonated and -Catenin Target Genes Deregulated in FNHβ






Known effect of -cateninβ
activation
Periportal genes
SDS Serine dehydratase −20.2 nd amino acid catabolism Repressed
GLS2 Glutaminase 2 (mitochondrial) −18.9 nd amino acid catabolism Repressed
HAL Histidine ammonia-lyase −5.9 nd amino acid catabolism Repressed
SDSL Serine dehydratase-like nd −2.2 amino acid catabolism
ASS Argininosuccinate synthetase −2.4 −2.1 amino acid catabolism Repressed
CPS1 Carbamoyl-phosphate synthetase 1 mitochondrial −2.2 −1.6 amino acid catabolism
GLDC Glycine dehydrogenase −2.3 nd amino acid catabolism Repressed
GNMT Glycine N-methyltransferase −6.5 nd amino acid metabolism Repressed
SLC7A2 Solute carrier family 7 (cationic amino acid transporter, y  system),+
member 2
−2.2 nd amino acid transporter Repressed
IGF1 Insulin-like growth factor 1 (somatomedin C) −2.7 −3.5 growth factor Repressed
ALDOB Aldolase B. fructose-bisphosphate −2.3 ns glycolysis Repressed
HES1 Hairy and enhancer of split 1 −2.7 −2.2 transcriptional regulator Repressed
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 na −1.9 xenobiotic metabolism
Pericentral genes
GLUL Glutamate-ammonia ligase (glutamine synthase) 3.7 2.3 glutamine synthesis Induced
RHBG Rhesus blood group. B glycoprotein 6.1 nd ammonium transporter Induced
LGR5 Leucine-rich repeat-containing G protein-coupled receptor 5 2 nd receptor Induced
TBX3 T-box 3 (ulnar mammary syndrome) 3.1 ns transcriptional regulator Induced
SLC13A3 Solute carrier family 13 (sodium-dependent dicarboxylate transporter)
member 3
2.6 nd dicarboxylic acid
transporter
Induced
SERPINE2 Serine (or cysteine) proteinase inhibitor member 2 2.2 nd regulation of proteolysis
Other genes regulated by -cateninβ
LAMA3 Laminin, alpha 3 4. 9 1.7 extracellular matrix Induced
CCND1 Cyclin D1 (PRAD1: parathyroid adenomatosis 1) 3.1 1.6 cell cycle Induced
SOX9 SRY (sex determining region Y)-box 9 4.1 nd transcriptional regulator Induced
SOX4 SRY (sex determining region Y)-box 4 2.2 ns transcriptional regulator Induced
ABCB1 ATP-binding cassette. sub-family B (MDR/TAP). member 1 2 na ABC transporter Induced
FOSB FBJ murine osteosarcoma viral oncogene homolog B −4.3 −2.2 transcriptional regulator Repressed
FOS V-fos FBJ murine osteosarcoma viral oncogene homolog na −4.6 transcriptional regulator Repressed
ns: not significant; na: not analyzed; nd: not done; NTL: non tumor-livers
